Rutaecarpine

Rutaecarpine

SCHEMBL288507

O=c1c2ccccc2nc2n1CCc1c-2[nH]c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 14/20 1.00
CYP1B1 Q16678 14/20 1.00
CYP1A2 P05177 13/20 1.00
PDE5A O76074 5/20 1.00
KDM4E B2RXH2 2/20 1.00
NPC1 O15118 2/20 1.00
ALDH1A1 P00352 2/20 1.00
TP53 P04637 2/20 1.00
POLB P06746 2/20 1.00
RAB9A P51151 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
LMNA P02545 1/20 1.00
CYP3A4 P08684 1/20 1.00
PKM P14618 1/20 1.00
TSHR P16473 1/20 1.00
PTGS1 P23219 1/20 1.00
PTGS2 P35354 1/20 1.00
THPO P40225 1/20 1.00
MTOR P42345 1/20 1.00
BLM P54132 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rutaecarpine SCHEMBL29693598 1.00 CYP1A1 (1.00) CYP1A1CYP1B1CYP1A2PDE5AKDM4E
Rutaecarpine SCHEMBL29406533 1.00 CYP1A1 (1.00) CYP1A1CYP1B1CYP1A2PDE5AKDM4E
SCHEMBL11047610 0.88 CYP1A1 (0.78) CYP1A1CYP1B1CYP1A2PDE5AKDM4E
SCHEMBL25150530 0.88 CYP1A1 (0.78) CYP1A1CYP1B1CYP1A2PDE5AKDM4E
SCHEMBL24753913 0.88 CYP1A1 (0.78) CYP1A1CYP1B1CYP1A2PDE5AKDM4E
SCHEMBL5740905 0.88 CYP1A1 (0.78) CYP1A1CYP1B1CYP1A2PDE5AKDM4E
SCHEMBL14297679 0.87 CYP1A1 (1.00) CYP1A1CYP1B1CYP1A2PDE5AKDM4E
SCHEMBL11045375 0.87 CYP1A1 (0.83) CYP1A1CYP1B1CYP1A2PDE5AKDM4E
SCHEMBL15500023 0.87 CYP1A1 (0.76) CYP1A1CYP1B1CYP1A2PDE5AKDM4E
SCHEMBL11050683 0.87 CYP1A1 (0.76) CYP1A1CYP1B1CYP1A2PDE5AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 EP claimed
CN-119930619-A Rutaecarpine derivative with multi-target antitumor activity and application thereof 中国人民解放军海军军医大学 2025-05-06 CN claimed
WO-2025076266-A1 TOPICAL COMPOSITION SIRENAS LLC (US) 2025-04-10 WO claimed
CN-119770590-A Child nerve soothing and distention eliminating foot membrane liquid containing Evodia rutaecarpa extract and preparation method thereof 北京中联民康中医药研究院 2025-04-08 CN claimed
CN-119751457-A Evodiamine derivative containing pyridine quaternary ammonium salt, preparation method and antibacterial application thereof 南华大学 2025-04-04 CN claimed
CN-119587447-A Evodia rutaecarpa soluble micro-needle for acupoint administration and preparation method and application thereof 沈阳药科大学 2025-03-11 CN claimed
CN-119306720-A Evodiamine derivative, rutaecarpine derivative, preparation method and application thereof 济宁市第一人民医院(济宁市医学科学研究院) 2025-01-14 CN claimed
CN-119291064-A Method for constructing characteristic spectrum of Shuangjin stomach intestine capsule 陕西科技大学 2025-01-10 CN claimed
WO-2024258363-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES SAHIN FIKRET (TR) 2024-12-19 WO claimed
CN-118777450-A Method for measuring content of multi-index components of erxiekang film 上海儿童营养中心(海南)有限公司 2024-10-15 CN claimed
US-20060264497-A1 Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health BIORESPONSE, L.L.C. 2006-11-23 US claimed
WO-2006105196-A2 DIINDOLYLMETHANE-BASED COMPOSITIONS AND METHODS OF USE THEREOF FOR PROMOTING ORAL MUCOSAL AND BONE HEALTH BIORESPONSE, L.L.C. (US) 2006-10-05 WO claimed
WO-2006023377-A2 BIOMIMETIC OF EVODIA RUTAECARPA FRUIT EXTRACT FOR AMELIORATION OF INFLAMMATION APPLIED GENETICS INCORPORATED DERMATICS (US) 2006-03-02 WO claimed
CN-1682807-A Composition for treating gastropathy and its preparing method ZHENGDA LUZHOU MED SCIENCE (CN) 2005-10-19 CN claimed
CN-1682829-A Wuji dripping pill for treating liver and stomach diseases and its preparing method ZHENGDA LUZHOU MED SCIENCE (CN) 2005-10-19 CN claimed
CN-1634641-A Process for separating and purifying organic compound by macroporous absorption resin-reverse osmosis membrane MENG YICHUN (CN) 2005-07-06 CN claimed
CN-1568998-A Blood pressure lowering medicine LI YUANJIAN (CN) 2005-01-26 CN claimed
CN-1312075-A Lipid metabolism-improving agent KYOWA HAKKO KOGYO KK (JP) 2001-09-12 CN claimed
US-6214831-B1 DECOMPOSING LIPIDS; ANTICHOLESTEROL AGENT KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-04-10 US claimed
US-4472399-A Indolo[2',3';3,4]pyrido[2,1-b]quinazoline-5-ones, a process for the preparation thereof, and diuretic compositions and methods using them CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1984-09-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264497-A1 Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health HPGDS, IDO1, IDO2 CYP1A1 1817/4885CYP1B1 2321/4885CYP1A2 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.